Xenios claims ‘significant’ 8-figure funding round

Lung and heart therapy device developer XENiOS AG said today it received a “significant” round of funding, claiming the amount was in the 8-figure range.

The Heilbronn, Germany-based company is developing a minimally invasive combined lung and heart therapy device on a single platform.

“No other company except XENiOS is offering minimally invasive disposable lung and heart therapies on 1 platform. The XENiOS platform provides fundamental advantages with its minimally invasive lung and heart therapies. Patients are awake and mobile. Self-determined patients facilitate improved outcomes. There is no ventilator-associated lung injury and pneumonia. Additionally, the XENiOS platform maintains a physiologic natural pulse designed to protect the heart,” managing director Dr. Georg Matheis said in prepared remarks.

The 2-device platform is being designed as an alternative to mechanical ventillation as well as treating cardiogenic shock or decompensated heart failure, the company said. The device can be used singly for either indication, or used to treat patients with concomitant lung and heart issues, XENiOS said.

The German company did not release any terms or details on the investment round, but said it was led by ZFHN.

“We are very pleased by the progress that XENiOS has achieved. This new investment in the company will fuel its commercial expansion in Europe and the United States,” ZFHN CEO Thomas Villinger said in a press release.

The post Xenios claims ‘significant’ 8-figure funding round appeared first on MassDevice.

from MassDevice http://ift.tt/1iMNtxO